Blood test may predict head and neck cancer progression

NCT ID NCT06678724

Recruiting now Knowledge-focused Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study is testing a new blood test that uses a microfluidic chip to detect cancer cells and immune cells in 30 patients with recurrent or metastatic head and neck cancer. The goal is to see if these blood markers can predict how long patients live without their cancer getting worse. The study does not provide any treatment, but aims to improve future prognostication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that helps doctors predict how head and neck cancer will progress and which treatments might work best.
What could go wrong: This is a very small, early observational study (30 people) that is not testing a treatment. It may not find clear patterns, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Neoplastic Cells, Circulating Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER METASTATIC HEAD AND NECK CANCERS- SQUAMOUS CELL RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

National Taiwan University HsinChu Branch
RECRUITING

Zhubei, HsinChu County, 302058, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.